News
CRDL
2.000
+1.01%
0.020
Weekly Report: what happened at CRDL last week (0429-0503)?
Weekly Report · 2d ago
Weekly Report: what happened at CRDL last week (0422-0426)?
Weekly Report · 04/29 09:58
Cardiol Therapeutics Sets Date for Shareholder Meeting
TipRanks · 04/26 12:57
CARDIOL THERAPEUTICS INC <CRDL.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $9
Reuters · 04/22 10:22
Buy Rating on Cardiol Therapeutics: Projected Blockbuster CardiolRx’s Strategic Advantages and Market Potential
TipRanks · 04/22 10:16
HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9
Benzinga · 04/22 10:08
CARDIOL THERAPEUTICS INC. <CRDL.TO>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING
Reuters · 04/22 10:07
Weekly Report: what happened at CRDL last week (0415-0419)?
Weekly Report · 04/22 09:55
CANADA RESEARCH ROUNDUP- ARC Resources, Cenovus Energy, Lundin Gold
Analysts revise their ratings and price targets on several Canadian companies. ARC Resources, Cenovus Energy, Lundin Gold and Suncor Energy raise their targets. Maple Leaf Foods initiates coverage with an outperform rating. Canadian Natural Resources Ltd and Advantage Energy raise target prices.
Reuters · 04/22 06:53
Weekly Report: what happened at CRDL last week (0408-0412)?
Weekly Report · 04/15 09:51
Weekly Report: what happened at CRDL last week (0401-0405)?
Weekly Report · 04/08 09:53
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)
TipRanks · 04/05 11:00
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023
Cardiol Therapeutics reported earnings per share of -9 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -12 cents. Cardiol TherAPEutics just reported results.
Investorplace · 04/02 13:53
Cardiol Therapeutics Q4 EPS $(0.09) Beats $(0.12) Estimate
Benzinga · 04/02 12:13
Cardiol Therapeutics Advances Heart Disease Trials
Cardiol Therapeutics Inc. Has achieved key milestones in its clinical trials for heart disease treatments. The company’s financial health appears robust, with sufficient cash reserves to fund operations into 2026. Cardiol's drug candidates have potential to treat heart disease .
TipRanks · 04/02 10:59
CARDIOL THERAPEUTICS: CASH AND CASH EQUIVALENTS OF $34.9 MLN AS OF DEC 31, 2023, WHICH FUNDS OPERATIONS INTO 2026
Reuters · 04/02 10:08
Weekly Report: what happened at CRDL last week (0325-0329)?
Weekly Report · 04/01 09:53
VERI, CHEK and MESO are among pre market gainers
VERI, CHEK and MESO are among pre market gainers. Mesoblast (MESO) and Cazoo Group (CZOO) are among the biggest pre market losers. Krispy Kreme and AirNet Technology are also on the move.
Seeking Alpha · 03/27 12:24
Weekly Report: what happened at CRDL last week (0318-0322)?
Weekly Report · 03/25 09:54
Weekly Report: what happened at CRDL last week (0311-0315)?
Weekly Report · 03/18 09:53
More
Webull provides a variety of real-time CRDL stock news. You can receive the latest news about Cardiol Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About CRDL
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.